Home › Oligodendroglioma
Pag-aaral pangklinika para sa Oligodendroglioma na nagre-recruit sa U.S.
16 pag-aaral para sa Oligodendroglioma ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Houston, TX4 pag-aaral
- Boston, MA4 pag-aaral
- Miami, FL4 pag-aaral
- Philadelphia, PA3 pag-aaral
- Aurora, CO3 pag-aaral
- Cleveland, OH3 pag-aaral
- St. Louis, MO3 pag-aaral
Ayos sa estado
- Colorado3 pag-aaral
- Florida4 pag-aaral
- Massachusetts4 pag-aaral
- Missouri3 pag-aaral
- New Jersey3 pag-aaral
- Ohio4 pag-aaral
- Pennsylvania3 pag-aaral
- Texas4 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 10, 2026 · NCT07703436Living Well With Brain Cancer: A Group-Based Intervention to Promote Whole-Person Well-Being
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT07628647Implantable Microdevice In Primary Brain Tumors
Nagre-recruitMaagang Phase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 21, 2026 · NCT04135807SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 19, 2026 · NCT05303519Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma.
Nagre-recruitPhase 2
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Okt 9, 2026 · NCT07439172A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
Nagre-recruitPhase 1
Edad 19 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT05698524SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
Nagre-recruitPhase 1/2
Edad 2 hanggang 24 · Lahat ng kasarian · Na-update Set 11, 2026 · NCT04923126FearLess in NeuroOncology
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT06989086HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Nagre-recruitPhase 1
36 Months – 22 Years · Lahat ng kasarian · Na-update Set 4, 2026 · NCT03911388Study of Olutasidenib and Temozolomide in HGG
Nagre-recruitPhase 2
Edad 12 hanggang 39 · Lahat ng kasarian · Na-update Set 1, 2026 · NCT06161974Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 16, 2026 · NCT04623931Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 24, 2026 · NCT07468136Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 21, 2026 · NCT07462507All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 20, 2026 · NCT05345002Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
Nagre-recruitPhase 1/2Malugod na tinatanggap ang malusog na boluntaryo
Edad 1 hanggang 21 · Lahat ng kasarian · Na-update Dis 8, 2025 · NCT05956821HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 21, 2025 · NCT06930846Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.